APA (7th ed.) Citation

Jr, W. W., MS, K., FV, F., DD, L., G, G., WH, T., . . . Kim, E. S. (2010). Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer (0008543X), 116(10), 2401. https://doi.org/10.1002/cncr.24996

Chicago Style (17th ed.) Citation

Jr, William WN, et al. "Phase 2 Study of Carboplatin, Docetaxel, and Bevacizumab as Frontline Treatment for Advanced Nonsmall-cell Lung Cancer." Cancer (0008543X) 116, no. 10 (2010): 2401. https://doi.org/10.1002/cncr.24996.

MLA (9th ed.) Citation

Jr, William WN, et al. "Phase 2 Study of Carboplatin, Docetaxel, and Bevacizumab as Frontline Treatment for Advanced Nonsmall-cell Lung Cancer." Cancer (0008543X), vol. 116, no. 10, 2010, p. 2401, https://doi.org/10.1002/cncr.24996.